BPC-157
Body Protection Compound-157
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
A 36-study systematic review contained 35 preclinical studies and one clinical study. A registered Phase I study had its results withdrawn and never published, and no completed randomized trial has demonstrated efficacy or safety.
The BPC-157 evidence base is essentially animal and in-vitro. A 2025 systematic review (Vasireddi et al.) screening 1993-2024 literature retained 36 studies, of which 35 were preclinical and only 1 was clinical, and a 2025 peer-reviewed review (Jozwiak et al., Pharmaceuticals) confirms nearly all data come from rat and mouse models. The single registered Phase I human safety study (2015, 42 healthy volunteers) had its results withdrawn and never published, and no completed randomized controlled trial has demonstrated efficacy or safety for any indication, so the honest grade is animal-only (grade 1), not preliminary-human.
Counted on the record: 1 human study, 0 randomized trials, 16 participants, 35 animal studies, 0 lab studies.
The cited 36-study review reports 35 preclinical studies and one clinical study. Human-study and participant totals remain unnormalized.
- FDA
- Unapproved drug. Placed on the FDA 503A Category 2 list (bulk substances that may present significant safety risks) in 2023; removed from Category 2 in April 2026 on procedural grounds after nominations were withdrawn, then referred to the Pharmacy Compounding Advisory Committee (PCAC meeting July 23, 2026). Not FDA-approved and not on the positive 503A bulks list.
- WADA
- Prohibited at all times, S0 Non-Approved Substances (2026 List; some sources also cite S2)
Reference only. Not medical advice.
What can go wrong
Stimulates angiogenesis via VEGFR-2, a mechanism that could theoretically feed an undetected tumor; sold only as a research chemical, and human safety is essentially unstudied with no long-term data.
Talk to a clinician before taking this, particularly if you have any history of cancer. The Atlas can tell you what has been studied about BPC-157. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
BPC-157 is a synthetic 15-amino-acid peptide studied for tendon, ligament, muscle, and gastrointestinal injury recovery through proposed angiogenesis and tissue-repair signaling.
The most discussed unapproved peptide in the world.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Combinations named above are how people use these compounds together, under names the community gave them. The combinations themselves have not been studied. Evidence for one compound is not evidence for a pair.
How it is supposed to work
BPC-157 is proposed to speed healing by switching on angiogenesis, the growth of new blood vessels, and by tuning the nitric-oxide system alongside several growth-factor pathways, including VEGFR2 (the main blood-vessel receptor) and the FAK-paxillin machinery that drives cell migration and tissue repair. It also appears to upregulate growth-hormone receptors in tendon cells and stabilize the gut lining. The single most important caveat sits underneath all of this: nearly every step of that mechanism is characterized in rat tissue. The human pathway is inferred from rodent work, not shown in people.
- Step 1AngiogenesisProposed activation of new blood-vessel growth into injured tissue.
- Step 2Nitric oxideProposed modulation of the nitric-oxide system involved in blood flow to a repair site.
- Step 3VEGFR2A blood-vessel receptor named among the proposed growth-factor pathways.
- Step 4FAK-paxillinCell-migration machinery associated with tissue repair.
- Step 5Growth-hormone receptorsReported upregulation in tendon cells alongside proposed stabilization of the gut lining.
Nearly every step is characterized in rat tissue. The human pathway is inferred from rodent work, not shown in people.
A synthetic pentadecapeptide composed of 15 amino acids.
BPC-157 remained intact during laboratory exposure to acidic human gastric fluid. This does not describe vial, lyophilized-powder, reconstitution, or storage stability.
- Class
- Pentadecapeptide
- Length
- 15 amino acids
- Half-life
- Under 30 minutes in rats and dogs
- Routes used
- Injection, oral, local
- Human dosing
- None validated
- Evidence base
- Mostly rat
The Single-Lab Problem
Here is what the marketing leaves out, and it is the whole story. A 2025 systematic review in the HSS Journal searched every database back to inception and found 35 preclinical studies and exactly one clinical study across all musculoskeletal uses. The single human trial that gets cited was small and low quality: about 16 people with knee pain, with relief reported in 7 of 12 in one arm. That is the entire human efficacy base for the most-discussed peptide in the world. Worse for the science, the great majority of the foundational studies trace to a single laboratory, Predrag Sikiric's group at the University of Zagreb, with limited independent replication by unaffiliated teams. Rat tendons heal faster and are structurally simpler than human tendons, and compounds that speed rat healing have a poor record of translating to people. Even regulators have flagged this: Australia's TGA noted the benefits are "largely unsubstantiated" and rest on studies that "largely originate from a single laboratory," and US Anti-Doping pointed out that human trials appear to have been started and then abandoned without published results. None of that proves it does not work. It means almost nobody has actually tested whether it does.
How it is taken
Injection (vial)
Freeze-dried BPC-157 salt intended to be mixed with sterile water or saline. A BPC-157 salt. Patent examples also describe optional ingredients such as mannitol. In a patent laboratory test, several 0.2% BPC-157 salt solutions retained about 99% of measured peptide after 120 days at 40 C. This was not a finished-vial shelf-life, reconstitution, or home-storage study. Patent formulation and laboratory stability testing. This is not an approved or standardized product.
Oral (capsule)
capsule One patent example contained 0.5 mg sodium BPC-157, 60 mg trehalose, 39 mg lactose, and 0.5 mg magnesium stearate. Intact BPC-157 remained recoverable after prolonged laboratory exposure to acidic human gastric fluid. This describes gastric-fluid exposure, not capsule shelf life or storage stability. A patent example, not a standardized commercial capsule.
Safety in detail
- We hold the whole safety record from animal studies, so human risk stays an open question.
- BPC-157 stimulates new blood vessel growth, the same signal a tumour uses, so clinicians avoid it in anyone with a cancer history.
Children and teenagers
There is no pediatric research on BPC-157, no approved use in anyone, and therefore no safety data whatsoever in children or adolescents. The only realistic way a minor encounters it is misuse, typically a teenage athlete or a young person chasing a physique or appearance goal, the same image-and-performance pressure that pulls adolescents toward anabolic steroids. This is not hypothetical: among those sanctioned in sport for BPC-157 was a 19-year-old. Because adult safety has never been established in a proper trial, use in anyone under 18 has no medical justification and carries entirely unknown risk. Marketing that reaches young athletes should be treated as a warning sign by parents and coaches, not a green light.
What people get wrong
Often saidIt is a natural compound your body makes
ActuallyIt is a synthetic fragment. The parent protein exists in gastric juice, but BPC-157 itself does not occur in nature.
Often saidDecades of safety data prove it is safe
ActuallyDecades of animal data exist, but published human safety evidence is limited to a very small clinical study. Animal evidence does not establish safety in people.
Who profits, and who pushes back
Dr. Eric Topol
None are proven. None have gone through adequate clinical trials.
Dr. Brad Stanfield
The leap from animal studies to safe human therapy remains unmade. Angiogenesis risk is real for anyone with cancer risk.
WADA
Prohibited at all times in sport. No therapeutic use exemption pathway exists.
Joe Rogan
Personal user for elbow tendinitis. No supplier relationship identified.
Gary Brecka
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Sells BPC-157 at $350-600/vial directly through Ultimate Human. Direct commercial interest in every mention. RFK Jr. ally.
Andrew Huberman
Covered with MD guests. Wellness sponsors (AG1, Eight Sleep) but no peptide-company money.
RFK Jr.
Policy advocacy. Claims the FDA suppressed the compound.
There is no approved BPC-157 product. Revenue instead flows to research-chemical vendors, wellness and telehealth businesses, and marketers promoting unapproved products. The July 2026 PCAC recommendation did not itself create an FDA-approved product or a completed Section 503A compounding pathway.
Where the research comes from
Most of the published research on this comes from one place. 62% of it is from Croatia. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Croatia | 62% |
| USA | 14% |
| Other | 14% |
| China | 10% |
Research published from: Croatia, USA, China.
How we got here
The 1993 paper described a larger gastric-juice protein called Body Protection Compound and fully characterized a synthetic 15-amino-acid fragment, BPC-157. It did not establish that intact BPC-157 itself occurs naturally in gastric juice. PLIVA developed the fragment under codes including PL-10, PLD-116 and PL 14736 for an inflammatory-bowel-disease program. The program did not produce an approved trade product, and the compound now circulates mainly under the research name BPC-157.
BPC-157 was first described in 1993 by Predrag Sikiric and colleagues at the University of Zagreb. Their paper described a larger protein isolated from human gastric juice and characterized a synthetic 15-amino-acid fragment, BPC-157. A substantial animal literature followed, much of it from the same research group. PLIVA later developed the compound as PL 14736 and reported a small ulcerative-colitis program in conference abstracts, but no approved medicine resulted. WADA prohibited BPC-157 in 2022, FDA placed it in Category 2 in 2023, and Australia published a specific scheduling decision in 2024. In 2026 FDA removed it from Category 2 after nomination withdrawal and sent it to PCAC, which recommended inclusion on the Section 503A bulks list. That advisory vote is not approval and final rulemaking remains outstanding.
Discovery and clinical development
1993 to 2005
First described in 1993, then developed as PL 14736 for inflammatory bowel disease
- 1993BPC-157 is first described in the literatureResearchers describe a larger protein isolated from human gastric juice and fully characterize a synthetic 15-amino-acid fragment called BPC-157.
- 1993The 15-amino-acid fragment is characterizedThe paper presents BPC-157 as the active fragment of the larger gastric protein. It does not establish that intact BPC-157 itself was isolated from human gastric juice.
- 2002-2005PLIVA develops PL 14736 for inflammatory bowel diseaseConference abstracts describe clinical development of PL 14736, including a 53-person randomized ulcerative-colitis enema study. The program did not lead to an approved medicine.
Preclinical evidence
2003 to 2025
A substantial animal literature, with very limited human evidence
- 2003Transected rat Achilles studyRats given BPC-157 after Achilles-tendon transection showed faster healing, and isolated tendon cells grew and spread more readily in laboratory tests.
- 2025Systematic review in orthopaedic sports medicineThe review retained 36 studies published from 1993 through 2024: 35 were preclinical and one was clinical.
- 2025Independent review and author responseAn independent review emphasizes that nearly all published evidence comes from animal models; researchers from the original group published a response.
- 2025Theoretical tumour concern raisedBecause proposed effects include new blood-vessel growth, reviewers raise a theoretical concern about accelerating an existing tumour. This has not been established in people.
Restriction
2022 to 2024
Sports and medicines regulators impose restrictions
- 2022WADA prohibits BPC-157BPC-157 is prohibited at all times in and out of competition under the non-approved-substances category.
- 2023FDA places it in Category 2FDA lists BPC-157 among bulk substances that may present significant safety risks for compounding. Category 2 is not an approval pathway.
- 22 May 2024Australia schedules BPC-157 by nameAustralia publishes a final Poisons Standard scheduling decision that specifically addresses BPC-157.
Compounding review
Feb 2026 to now
Public policy support leads to FDA review, but not approval
- 27 Feb 2026HHS Secretary publicly backs wider peptide accessIn a podcast interview, the HHS Secretary says he expects access to roughly fourteen peptides to expand. The statement is not an FDA reclassification or approval.
- 22 Apr 2026FDA removes BPC-157 from Category 2 after nomination withdrawalFDA records the removal after the nominators withdrew their submissions and announces a PCAC review. Removal from Category 2 is not approval or inclusion on the Section 503A bulks list.
- 23 Jul 2026PCAC recommends inclusion by an 8 to 6 voteThe advisory committee recommends BPC-157 for the Section 503A bulks list, with one abstention. The vote is advisory; inclusion still requires notice-and-comment rulemaking.
The numbers behind the grade
- Human RCTs
- 1 (small)
- Preclinical studies
- 35+
- Originating lab
- Zagreb
- WADA
- Prohibited (S0)
- FDA
- Under review
- Discovered
- ~1993
The people taking it
Users are mostly men between 25 and 50, concentrated in strength training, combat sport, and anti-ageing. Sellers aim their marketing at athletes and weightlifters.
The single most-discussed unapproved peptide in the world, and the one whose gap between online enthusiasm and actual human evidence is widest. Known popularly as "the healing peptide" or "the lifter's peptide," it is searched, sold and debated far out of proportion to what has been proven about it.
Hard demographic data does not exist for BPC-157, because gray-market use is unregulated and uncounted, so any precise breakdown by race or exact age would be invented. What the visible pattern shows is a user base skewed strongly male and concentrated in three overlapping worlds: strength and physique training, combat sport, and biohacking or anti-aging. Typical users are adults roughly 25 to 50. Australia's regulator described the target population bluntly as facing "a high risk of misuse within athletic, fitness, wellness and anti-ageing consumer markets," which is as close to an official demographic sketch as exists. Sellers themselves, by their own marketing, aim mainly at athletes and weightlifters.
Used worldwide, almost entirely off-label and gray-market, for musculoskeletal injury recovery, joint and tendon pain, and gut health, with a secondary anti-aging and general-recovery following. Concentrated in the United States and in strong gym-culture markets, and banned for any athlete under the World Anti-Doping Code.
Set against the alternatives
BPC-157 is most often discussed alongside TB-500 (thymosin beta-4 fragment), with which it is frequently stacked for injury recovery. The two share the same predicament: heavy animal interest, almost no human trial data, and a WADA ban. A newer variant, pentadecapeptide arginate or PDA, is marketed as a more stable "upgraded" BPC-157, but it is the same core sequence with no published human evidence of its own, so the "1000x more stable" claim is vendor marketing rather than a demonstrated clinical advantage. Measured against established options for the same injuries, platelet-rich plasma and structured physical therapy, BPC-157 has far less human evidence, not more. Its real distinction is not efficacy data but popularity.
What we do not know
- Whether it actually works in humans at all, since the entire human efficacy base is one small low-quality study.
- Whether the theoretical cancer-acceleration risk is real, protective, or neutral in people.
- Why multiple human trials appear to have been started and then abandoned without published results.
- What a proper independent, multi-dose, long-term randomized trial would show, which has never been run.
What could change
After the July 2026 advisory votePCAC recommended inclusion on the Section 503A bulks list, but FDA and HHS still must complete notice-and-comment rulemaking.Independent human trialsThe central evidence gap is still a sufficiently powered, independently run human trial with validated dosing and follow-up.Gut and IBD researchThe original clinical program focused on ulcerative colitis, but the available reports are too small and incomplete to establish benefit.Formulation developmentRecent reviews emphasize that a validated pharmaceutical formulation and dosing regimen have not been established.
Legal status
BPC-157 is not an FDA-approved drug and is not on the positive Section 503A bulks list. FDA removed it from Category 2 in April 2026 after the underlying nominations were withdrawn, then asked PCAC to review it. PCAC recommended inclusion in July 2026, but the vote was advisory and did not itself authorize compounding. Products continue to be marketed by research-chemical sellers, while WADA prohibits athlete use at all times.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
$3–8 per mg
Gray market · research vial
Common 5 mg vials near $55 and 10 mg vials near $70.
Prescription · compounded
Where a clinician will write for it, plus physician and telehealth fees.
Topical
Two real routes exist in 2026. Online research-chemical vendors sell it without a prescription, labeled for research use only, with quality that ranges from solid to dangerous; the only meaningful safeguard is an independent third-party certificate of analysis showing HPLC purity above about 98%, and a missing certificate is a reason to walk away. The second route is a compounding pharmacy via a telehealth or wellness clinic, which requires a prescription and costs more but offers cGMP quality control. Importing from overseas pharmacies is possible but legally murkier and prone to customs seizure, especially from China and India.
Gray-market research vials run roughly $3 to $8 per milligram, with common 5 mg vials near $55 and 10 mg vials near $70. Compounded prescription BPC-157, where a clinician will write for it, starts around $150 a month plus physician and telehealth fees. International or overseas-pharmacy sources are often advertised as cheaper, but customs seizure risk and unverifiable quality usually erase the savings. The cost gap is itself a driver of the gray market: the cheapest route is also the least accountable.
Most BPC-157 active ingredient is synthesized in China, with India a secondary source, regardless of where the finished vial is sold or what flag the website flies. Some US vendors genuinely synthesize or finish domestically, but "USA made" on a label is not verifiable without independent testing. Purity, identity and contamination vary dramatically between sellers, which is why a current, independent certificate of analysis matters more than any marketing claim.
United StatesA mix of domestic "research peptide" labs that advertise US synthesis and product that is repackaged from imported bulk. Compounded BPC-157, where prescribed, uses bulk active ingredient that itself often originates overseas.ChinaThe dominant global manufacturing hub for peptide active ingredient. Most gray-market BPC-157 worldwide is synthesized here, then sold directly to consumers online or shipped to repackagers and clinics abroad.IndiaA secondary manufacturing and export source, frequently named alongside China in customs seizures of peptide shipments.European Union & UKLargely supplied by online vendors importing finished vials or bulk from Asia. No approved product exists; frameworks treat it as unlicensed.AustraliaOfficially the strictest market: a Schedule 4 prescription-only medicine that almost nobody can legally obtain, so supply is overwhelmingly illicit import, much of it intercepted by customs.Mexico & South AmericaReached through online vendors and regional gray markets; some buyers in stricter countries source here or through cross-border pharmacies.Eastern Europe & Middle EastGym-culture demand met mostly through online import from Asian manufacturers; little local production and patchy regulation.
At a glance
- Amino acid sequence
- GEPPPGKPADDAGLV
- Amino acids
- 15
- Half-life
- Under 30 minutes in rats and dogs
- CAS
- 137525-51-0
- Mol. weight
- 1419.5 g/mol
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about BPC-157.
Nothing outstanding on this one.
Sources
FDA classifies BPC-157 as a bulk substance that may present significant safety risks (503A Category 2), and it is not FDA-approved for compounding or human use
BPC-157 is an unapproved drug, not a dietary ingredient, cannot be legally prescribed or sold, is often labeled 'research use only / not for human consumption,' and is on WADA class S0
BPC-157 is prohibited for athletes as an experimental, non-approved peptide
S0 covers pharmacological substances with no approval by any government health authority for human therapeutic use, prohibited at all times
Systematic review of BPC-157 in orthopaedic sports medicine retained 36 studies (35 preclinical, 1 clinical) from 1993-2024 literature
Nearly all BPC-157 data are limited to small animal models; not approved for human use; angiogenesis via VEGFR-2 raises tumor concern; metabolite oxidative-stress and nitric-oxide safety flags
Jozwiak, Bauer, Kamysz, Kleczkowska, Pharmaceuticals (Basel) 2025;18(2):185
A BPC-157 human trial for acute hamstring muscle strain is registered on ClinicalTrials.gov (recruiting, not completed)
FDA removed BPC-157 acetate and free base from 503A Category 2 in April 2026 on procedural grounds and scheduled a PCAC review for July 23, 2026; removal is not approval
No published randomized human trial demonstrates BPC-157 efficacy or safety; the human evidence base is a single small open-label pilot
This seller promotes BPC-157 for accelerated repair of tendons, ligaments, muscle, and the gut lining.
A narrative review reports strong gastric-fluid stability but no validated pharmaceutical formulation, no validated dosing regimen, and fewer than 30 participants across three uncontrolled human pilot studies.
Patent examples describe injectable and oral BPC-157 salt formulations. In one laboratory test, several 0.2% aqueous salt solutions retained about 99% of measured peptide after 120 days at 40 C. This is not a finished-vial shelf-life study.
In rats and dogs, intact BPC-157 had an elimination half-life under 30 minutes and was no longer detectable four hours after dosing. Four hours is a detection endpoint, not the half-life or vial stability.
The first published description in 1993 characterizes the 15-amino-acid BPC-157 fragment of a larger gastric-juice protein.
The 2003 rat study reports faster healing after Achilles-tendon transection and tendocyte growth in vitro.
FDA summarizes the compound history, the PL 14736 clinical program, nonclinical evidence, human evidence and safety record.
Australia published a final scheduling decision specifically addressing BPC-157 in May 2024.
Therapeutic Goods Administration, final scheduling decision for BPC-157, May 22, 2024.
FDA records the 2026 removal of BPC-157 from Category 2 after nomination withdrawal and the planned PCAC review.
FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated May 14, 2026.
The HHS Secretary publicly discussed expanding peptide access; the statement was not itself an FDA reclassification.
The official FDA meeting page records the July 2026 PCAC review and supporting materials.
FDA, July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
FDA maintains the official Section 503A bulks list and explains that adding a substance requires the agency to complete its regulatory process.
FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
A phase 1 trial of PCO-02, whose active ingredient is BPC-157, registered an estimated 42 healthy volunteers with a March 2016 completion date. The registration was last updated on December 17, 2015, its status reads unknown, and no results are posted.
A review from the originating Croatian group collects consistent healing of several external and internal gastrointestinal fistula models after BPC 157. Every healing result it gathers comes from rats.
The studies that matter
Vasireddi et al., HSS Journal (systematic review)2025
Searched all databases to 2024: 35 preclinical studies and only 1 clinical study for musculoskeletal use. The cleanest summary of how thin the human evidence is.
Human knee-pain pilotreported
A small, low-quality study of about 16 people, with pain relief in 7 of 12 in one arm after a BPC-157 knee injection. The single most-cited human result.
Staresinic et al., transected rat Achilles2003
Accelerated tendon healing with greater failure load in rats, the founding musculoskeletal finding and the template for most that followed.
Sikiric laboratory series1990s-2020s
Hundreds of rodent studies across tendon, muscle, gut, nerve, bone and brain, almost all from one Croatian group, with limited outside replication.
PLIVA human IBD program1990s
Early human work in inflammatory bowel disease reported as positive but never completed to approval, an example of the abandoned-trial pattern.
Jozwiak vs Sikiric exchange (Pharmaceuticals)2025
A published back-and-forth in which critics argue that without independent multi-dose, long-term and randomized trials it cannot be called a legitimate therapy, and the originating group defends its safety.